Zhang Jialong, Chen Xinyu, Yan Chong, Gu Xinyu, Zhu Wenhua, Cao Xuwei, Zhou Lei, Luo Sushan, Lin Jie, Li Zunbo, Lu Jiahong, Zhao Chongbo, Qiao Kai, Yu Xuefan, Xi Jianying
Department of Neurology, Huashan Rare Disease Center, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
Department of Neurology, Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, China.
Orphanet J Rare Dis. 2025 May 29;20(1):259. doi: 10.1186/s13023-025-03823-z.
Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the key enzyme initiating protein O- and N-glycosylation at the postsynaptic membrane. Variants in GFPT1 gene cause congenital myasthenic (GFPT1-CMS). However, the understanding of the phenotype and genetic spectrum of GFPT1-CMS remains limited.
A total of 24 patients with GFPT1-CMS from 22 Han Chinese families across four neuromuscular disease centers were included in this study. Clinical assessments involved detailed medical histories, muscle biopsies, and electrophysiological studies. GFPT1 variants were identified using targeted next-generation sequencing or WES. Additionally, published GFPT1-CMS case data from 2011 to 2024 were compiled and combined with this cohort for genotype-phenotype correlation analysis.
In addition to the limb girdle myasthenia pattern, our cohort presented with extraocular involvement including eyelid ptosis and mild ophthalmoparesis (25.0%), facial weakness (20.8%) and a relatively high prevalence of distal weakness (62.5%). Electrophysiological testing revealed myopathic changes in 95.0% of cases and decremental CMAPs in all cases during RNS. We found that c.331 C > T is a hotspot variant in GFPT1-CMS patients and may have a founder effect in the Chinese population. Patients with homozygous null variants presented a more severe phenotype, including earlier onset and more frequent bulbar involvement.
We have described the clinical features and variant spectrum in a cohort of 24 Chinese GFPT1-CMS patients. Our findings update the understanding of clinical manifestation, pathological features and mutational spectrum in GFPT1-CMS patients.
谷氨酰胺-果糖-6-磷酸转氨酶1(GFPT1)是在突触后膜启动蛋白质O-糖基化和N-糖基化的关键酶。GFPT1基因变异导致先天性肌无力(GFPT1-CMS)。然而,对GFPT1-CMS的表型和基因谱的了解仍然有限。
本研究纳入了来自四个神经肌肉疾病中心的22个汉族家庭的24例GFPT1-CMS患者。临床评估包括详细的病史、肌肉活检和电生理研究。使用靶向二代测序或全外显子测序鉴定GFPT1变异。此外,收集了2011年至2024年已发表的GFPT1-CMS病例数据,并与该队列进行合并,以进行基因型-表型相关性分析。
除了肢带型肌无力模式外,我们的队列还表现为眼外肌受累,包括眼睑下垂和轻度眼肌麻痹(25.0%)、面部无力(20.8%)以及相对较高的远端无力患病率(62.5%)。电生理测试显示95.0%的病例有肌病性改变,重复神经电刺激(RNS)时所有病例复合肌肉动作电位(CMAP)递减。我们发现c.331 C>T是GFPT1-CMS患者中的一个热点变异,可能在中国人群中存在奠基者效应。纯合无效变异的患者表现出更严重的表型,包括发病更早和更频繁的延髓受累。
我们描述了24例中国GFPT1-CMS患者队列的临床特征和变异谱。我们的发现更新了对GFPT1-CMS患者临床表现、病理特征和突变谱的认识。